Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last ¥414.00 JPY
Change Today -10.00 / -2.36%
Volume 7.8M
3401 On Other Exchanges
3401 is not on other exchanges.
As of 2:00 AM 04/17/15 All times are local (Market data is delayed by at least 15 minutes).

teijin ltd (3401) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/8/15 - ¥437.00
52 Week Low
05/12/14 - ¥224.00
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for TEIJIN LTD (3401)

Related News

No related news articles were found.

teijin ltd (3401) Related Businessweek News

No Related Businessweek News Found

teijin ltd (3401) Details

Teijin Limited, together with its subsidiaries, provides various solutions in transportation, information and electronics, safety and protection, environment and energy, and healthcare areas in Japan and internationally. The company’s Advanced Fibers and Composites segment offers para-aramid fibers, meta-aramid fibers, carbon fibers, carbon fiber composite materials, artificial leather, polyester fibers, and Polyethylene naphthalate (PEN) fibers. Its Electronics Materials and Performance Polymer Products segment provides polycarbonate resins, PEN resins, polyethylene terephthalate films, PEN films, and processed films. The company’s Healthcare segment offers pharmaceuticals, including Bonalon and Onealfa for the treatment of osteoporosis; Synvisc to treat pain associated with osteoarthritis of the knee; Mucosolvan, an expectorant; Spiropent, a bronchodilator; Atrovent, a prophylaxis for bronchial constriction; Rhinocort for treating allergic rhinitis; Alvesco, an inhaled corticosteroid agent for asthma; Feburic to treat hyperuricemia and gout; Tricor for the treatment of hyperlipidemia; Somatuline to treat acromegaly; Venilon for the severe infectious diseases treatment; Laxoberon, a laxative; and Bonalfa to treat psoriasis. This segment also provides sonic accelerated fracture healing systems, therapeutic oxygen concentrators, and sleep disorder diagnostic systems, as well as non-invasive positive pressure ventilators for sufferers of sleep apnea syndrome. Its Trading and Retail segment sells and trades fibrous raw material, apparel, industrial materials, and performance polymer products. The company also offers IT services in the healthcare field, Web-based enterprise resource planning services, and digital content management services; content distribution services for mobile phones and smartphones, and e-commerce services; and polyester raw materials and polymerization services. Teijin Limited was founded in 1918 and is headquartered in Osaka, Japan.

15,756 Employees
Last Reported Date: 11/26/14
Founded in 1918

teijin ltd (3401) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

teijin ltd (3401) Key Developments

Teijin and Taisho Pharmaceutical Holdings Co., Ltd. Sign Sales Agreement for New Anti-Inflammatory Analgesic Patch Formulation

Teijin Limited announced its agreement with Taisho Pharmaceutical Co., Ltd., for the distribution rights in Japan to TT-063, an anti-inflammatory analgesic patch formulation for the anticipated indication of osteoarthritis. The agreement allows TT-063 to be co-marketed by Teijin Pharma Limited.

Teijin to Establish New Medical Devices JV Firm with Nakashima Medical Co

Teijin is setting up a new 50:50 medical devices joint venture firm with Nakashima Medical Co that will be established from 1 April this year. Teijin will acquire new shares of Nakashima Medical Co, through a third-party allotment, to establish the new joint venture firm which will be called Teijin Nakashima Medical. Teijin Nakashima Medical will be involved in the development, manufacturing and sales of medical devices, including joint prostheses and trauma implants. The third-party allocation of new stock is worth around JPY 1.5 billion ($12.6 million).

Teijin Ltd., Q3 2015 Earnings Call, Feb 03, 2015

Teijin Ltd., Q3 2015 Earnings Call, Feb 03, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
3401:JP ¥414.00 JPY -10.00

3401 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Celanese Corp $67.18 USD +9.04
Koninklijke DSM NV €51.26 EUR -1.61
LANXESS AG €47.83 EUR -1.99
Mitsui Chemicals Inc ¥392.00 JPY -5.00
Trinseo SA $22.00 USD -0.47
View Industry Companies

Industry Analysis


Industry Average

Valuation 3401 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 0.5x
Price/Book 1.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TEIJIN LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at